Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021


ATA2271 targets difficult-to-treat solid tumors using proprietary 1XX CAR signaling and intrinsic PD-1 checkpoint inhibition technology Ongoing Phase 1 dose-escalation trial in advanced mesothelioma shows promising early safety and persistence of armored CAR T cells in patients Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy,…

Read More

Freenome Partners with Siemens Healthineers for Breast Cancer Research


— Collaboration leverages imaging, diagnostic and multiomic expertise to identify new, significant biomarkers to improve the detection of breast cancer Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Dec. 1, 2021 /PRNewswire/ — Freenome, a privately held biotech company, announced a partnership with Siemens Healthineers to collaborate in multiomics and radiomic breast cancer diagnostics to identify…

Read More

Ontario Institute for Cancer Research announces funding for sixteen studies that support early detection of cancer, the development of new diagnostics to guide therapy and improved treatment options for patients


Funding provides $16 million in support for Ontario cancer research Excerpt from the Press Release: December 2, 2021—Toronto—Today the Ontario Institute for Cancer Research (OICR) announced funding for 16 studies as part of the Institute’s new Clinical Translation Pathway (CTP). These awards support pre-clinical research and new clinical trials that have a focus on early…

Read More

New funding from the Ontario Institute for Cancer Research supports projects developing methods for cancer detection and tools to facilitate better treatment decisions for high-risk cancer patients


December 1, 2021—Toronto— Today the Ontario Institute for Cancer Research (OICR) announced renewed funding for its Adaptive Oncology (AO) research theme, which includes funding for three new research projects with the potential to have rapid clinical impact. Excerpt from the Press Release: he Adaptive Oncology theme was developed to anticipate and counter tumour evolution and…

Read More

Drug discovery quantum computing project receives £6.85m grant


A consortium of quantum computing companies including Medicines Discovery Catapult (MDC) has secured a £6.85 million grant for a project that is looking to improve drug discovery in cancer. Excerpt from the Press Release: The consortium is being led by SEEQC and will look to accelerate the use of quantum computing within pharmaceutical research to…

Read More

Blood Cancer UK partners with RareCan to improve delivery of clinical trials


Charity Blood Cancer UK has teamed up with oncology company RareCan to support the organisation’s delivery of clinical trials focussed on the prevention, diagnosis, or treatment of rare cancers. Excerpt from the Press Release: Blood cancer The partnership will see Blood Cancer UK join the charity network GIST Cancer UK as RareCan’s partner. The aim…

Read More

BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types


– The potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) has the potential to impact approximately 500,000 cancer patients with unmet therapeutic needs – BridgeBio and Helsinn have also established a non-exclusive framework agreement to identify and potentially co-develop and co-commercialize additional small molecule targeted oncology therapies – This framework agreement leverages BridgeBio’s…

Read More

Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)


The interventional, multicenter, open-label Phase 2 basket trial will evaluate the safety and efficacy of milademetan in patients with MDM2-amplified advanced solid tumors Excerpt from the Press Release: NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first patient…

Read More

CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer


Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Nov. 18, 2021– Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology. (instead of CNSide detected CSF tumor cells…

Read More

Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Detection


Excerpt from the Press Release: MADISON, Wis. and PHILADELPHIA, Nov. 18, 2021 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) today announced an agreement with Jefferson Health (Jefferson) to conduct research on a new blood-based, multi-cancer earlier detection (MCED) test. This unique effort will engage primary care and specialty providers, care coordinators, and patients from diverse populations across the Jefferson enterprise in research that aims…

Read More